Barry Klark Forman

US Patent:

6413994, Jul 2, 2002

Filed:

Feb 16, 2001

Appl. No.:

09/788070

Inventors:

Ronald M. Evans - La Jolla CA
Barry M. Forman - La Jolla CA

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

A61K 3144

US Classification:

514357, 5142222, 5142232, 5142265, 5142275, 5142288, 514241, 514254, 514257, 514365, 514367

Abstract:

In accordance with the present invention, there is provided a class of compounds which are capable of modulating processes mediated by peroxisome proliferator activated receptor-gamma (PPAR-). The identification of such compounds makes it possible to intervene in PPAR- mediated pathways.

US Patent:

6416957, Jul 9, 2002

Filed:

Oct 24, 2000

Appl. No.:

09/696443

Inventors:

Ronald M. Evans - La Jolla CA
Barry M. Forman - La Jolla CA
Cary A. Weinberger - Carrboro NC

Assignee:

The Salk Institute for Biological Studies - La Jolla CA
Ligand Pharmaceuticals, Inc. - San Diego CA
The Government of the United States of America - Washington DC

International Classification:

G01N 3353

US Classification:

435 71, 530350

Abstract:

Farnesyl pyrophosphate, the metabolically active form of farnesol, is a key precursor in the synthesis of cholesterol, carotenoids, steroid hormones, bile acids and other molecules involved in cellular growth and metabolism. A nuclear receptor has been identified that is transcriptionally activated by farnesol and related molecules. This novel signaling pathway can be modulated by the use of key metabolic intermediates (or analogs and/or derivatives thereof) as transcriptional regulatory signals.

US Patent:

6458926, Oct 1, 2002

Filed:

Jun 18, 1997

Appl. No.:

08/877966

Inventors:

Ronald M. Evans - La Jolla CA
Barry M. Forman - La Jolla CA
Kazuhiko Umesono - Nara, JP

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

C07K 14435

US Classification:

530350

Abstract:

Heterodimerization is a common paradigm among eucaryotic transcription factors, though it remains unclear how individual monomers contribute to the overall transcriptional activities of the complex. The 9-cis retinoic acid receptor (RXR) serves as a common heterodimerization partner for several nuclear receptors including the thyroid hormone (T R), retinoic acid (RAR) and vitamin D receptors. A strategy has been devised to examine the transcriptional properties of each receptor individually or when tethered to a heterodimeric partner. It has been found that the intrinsic activity of RXR is masked in RXR-T R and RXR-RAR heterodimers. In contrast, a novel RXR-Nurr1 heterodimer described herein is highly responsive to RXR ligands, suggesting that different partners exert unique allosteric control over the RXR response. These findings establish a novel 9-cis retinoic acid response pathway and resolve the paradox as to how T R, RAR and VDR contribute to distinct physiologic pathways while sharing a common RXR subunit.

US Patent:

6586455, Jul 1, 2003

Filed:

Feb 1, 2000

Appl. No.:

09/331534

Inventors:

Ronald M. Evans - La Jolla CA
Peter Tontonoz - Los Angeles CA
Bruce M. Spiegelman - Waban MA
Barry M. Forman - Newport Beach CA

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

A61K 314406

US Classification:

514369, 514356, 514569, 424464

Abstract:

In accordance with the present invention, it has been discovered that PPAR is expressed consistently in each of the major histologic types of human liposarcoma. It has further been discovered that maximal activation of PPAR with exogenous ligand (a thiazolidinedione or derivative thereof) promotes terminal differentiation of primary human liposarcoma cells. It has still further been discovered that RXR-specific ligands are also potent adipogenic agents in cells expressing the PPAR/RXR heterodimer, and that simultaneous treatment of liposarcoma cells with a thiazolidinedionyl moiety (a PPAR-selective class of compounds) and an RXR-specific ligand results in an additive stimulation of differentiation. Accordingly, according to the invention, there have been identified compositions which are useful for the treatment of liposarcomas.

US Patent:

6605627, Aug 12, 2003

Filed:

May 8, 2002

Appl. No.:

10/142373

Inventors:

Ronald M. Evans - La Jolla CA
Barry M. Forman - La Jolla CA

Assignee:

The Salk Insitute for Biological Studies - La Jolla CA

International Classification:

A61K 3144

US Classification:

514357, 5142222, 5142232, 5142265, 5142288, 514241, 514254, 514257, 514365, 514367, 514824

Abstract:

In accordance with the present invention, there is provided a class of compounds which are capable of modulating processes mediated by peroxisome proliferator activated receptor-gamma (PPAR-). The identification of such compounds makes it possible to intervene in PPAR- mediated pathways.

US Patent:

6830882, Dec 14, 2004

Filed:

Sep 21, 1998

Appl. No.:

09/155252

Inventors:

Ronald Mark Evans - La Jolla CA
Barry Marc Forman - Diamond Bar CA

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

C12Q 168

US Classification:

435 6, 435 71, 4352523, 4353201, 435325, 530300, 530350, 536 231

Abstract:

In accordance with the present invention, there are provided a class of compounds which are capable of selectively modulating processes mediated by peroxisome proliferator activated receptor-gamma (PPAR-). The identification of such compounds makes possible the selective intervention in PPAR- mediated pathways, without exerting inadvertent effects on pathways mediated by other PPAR isoforms.

US Patent:

7041498, May 9, 2006

Filed:

May 24, 2002

Appl. No.:

10/155379

Inventors:

Ronald M. Evans - La Jolla CA, US
Barry M. Forman - Newport Beach CA, US
Cary A. Weinberger - Carrboro NC, US

Assignee:

The Salk Institute for Biological Studies - La Jolla CA
Ligand Pharmaceuticals, Inc. - San Diego CA
The Government of the United States of America - Washington DC

International Classification:

C12N 5/00
C12N 15/24
C07H 17/00

US Classification:

435325, 4353201, 4352523, 536 231

Abstract:

Farnesyl pyrophosphate, the metabolically active form of farnesol, is a key precursor in the synthesis of cholesterol, carotenoids, steroid hormones, bile acids and other molecules involved in cellular growth and metabolism. A nuclear receptor has been identified that is transcriptionally activated by farnesol and related molecules. This novel signaling pathway can be modulated by the use of key metabolic intermediates (or analogs and/or derivatives thereof) as transcriptional regulatory signals.

US Patent:

7439027, Oct 21, 2008

Filed:

Apr 28, 2006

Appl. No.:

11/413604

Inventors:

Ronald M Evans - La Jolla CA, US
Barry M Forman - La Jolla CA, US
Cary A Weinberger - Carrboro NC, US

Assignee:

The Salk Institute for Biological Studies - La Jolla CA
Ligand Pharmaceuticals, Inc. - San Diego CA
United States of America - Washington DC

International Classification:

G01N 33/53
C07K 14/00

US Classification:

435 71, 530350

Abstract:

Farnesyl pyrophosphate, the metabolically active form of farnesol, is a key precursor in the synthesis of cholesterol, carotenoids, steroid hormones, bile acids and other molecules involved in cellular growth and metabolism. A nuclear receptor has been identified that is transcriptionally activated by farnesol and related molecules. This novel signaling pathway can be modulated by the use of key metabolic intermediates (or analogs and/or derivatives thereof) as transcriptional regulatory signals.